Population Screening for Prostate Cancer and Emerging Concepts for Young Men

Clinical Prostate Cancer

Volumn 2, Issue 2, 2003, Pages 87-97

  Moul, Judd W ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Center for Prostate Disease Research   (United States)

Author keywords

Age; Prostate specific antigen; Race; Risk factors

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; ALTERNATIVE MEDICINE; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; EARLY DIAGNOSIS; EJACULATION; ETHNOLOGY; EXERCISE; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; MASS SCREENING; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; UNITED STATES;

EID: 0142053944     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.015     Document Type: Review

References (123)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Walsh PC. Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med 1993; 119:948-949.
3. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 1995; 333:1401-1405.
4. Mettlin C, Jones G, Averette H, et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993; 43:42-46.
5. American Urological Association. Early Detection of Prostate and Cancer Use of Transrectal Ultrasound. In: American Urological Association 1992 Policy Statement Book. Baltimore, MD: American Urological Association, 1992:4-20.
6. US Preventive Service Task Force. Screening for prostate cancer. Guide to Clinical Preventive Services, 2nd ed. Baltimore, MD: Williams and Wilkins, 1996:119.
7. American College of Physicians. Screening for prostate cancer. Ann Intern Med 1997; 126:480-484.
8. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270:948-954.
9. Catalona WJ. Screening for prostate cancer. N Engl J Med 1996; 334:667.
10. Morrison AS. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening. Int J Epidemiol 1982; 11:261-267.
11. Jacobson SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate specific-antigen. JAMA 1995; 274:1455.
12. Stephenson RA. Population-based prostate cancer trends in the PSA era: data from the Surveillance, Epidemiology, and End Reults (SEER) Program. Monogr Urol 1998; 19:3-19.
13. Farkas A, Schneider D, Perrotti M, et al. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52:444-448.
14. Schwartz KL, Severson RK, Gurney JG, et al. Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. Cancer 1996; 78:1260-1266.
15. Threlfall TJ, English DR, Rouse IL. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust 1998; 169:21-24.
16. Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999; 161:529-533.
17. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312:1604-1608.
18. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15:331-335.
19. Lefevre ML. Prostate cancer screening: more harm than good? Am Fam Physician 1998; 58:432-438.
20. Sun L, Gancarczyk K, Paquette EL, et al. Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database and analysis in the PSA era. Urol Oncol 2001; 6:203-209.
21. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270:860-864.
22. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335:304-310.
23. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330:242-248.
24. Smith CV, Bauer JJ, Connelly RR, et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 2000; 164:1964-1967.
25. Herold DM, Hanlon AL, Movsas B, et al. Age-related prostate cancer metastases. Urology 1998; 51:985-990.
26. Carter HB, Epstein JI, Partin AW. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53:126-130.
27. Litwiller SE, Djavan B, Klopukh BV, et al. Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: changing trends over a 10-year period (1984-1994). Dallas Outcomes Research Group for Urological Disorders. Urology 1995; 45:813-822.
28. Newcomer LM, Stanford JL, Blumenstein BA, et al. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997; 158:1427-1430.
29. Perez CA, Hanks GE, Leibel SA, et al. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer 1993; 72:3156-3173.
30. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152:1837-1842.
31. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152:1732-1736.
32. Vijayakumar S, Vaida F, Weichselbaum R, et al. Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am 1998; 4:27-34.
33. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-1451.
34. Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001; 166:1322-1327.
35. Preston DM, Bauer JJ, Connelly RR, et al. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995. Urology 1999; 53:131-138.
36. Schwartz KL, Grignon DJ, Sakr WA, et al. Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996. Urology 1999; 53:769-774.
37. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91:1017-1024.
38. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906.
39. Lee F, Siders DB, Torp-Pedersen ST, et al. Prostate cancer: transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer. Cancer 1991; 67:1132-1142.
40. Chodak GW. The role of watchful waiting in the management of localized prostate cancer. J Urol 1994; 152:1766-1768.
41. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994; 152:1753-1756.
42. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280:975-980.
43. Gilliland FD, Hunt WC, Key CR. Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen ERA. Urology 1996; 48:67-71.
44. Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer-part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91:1033-1039.
45. Paquette EL, Sun L, Paquette LR, et al. Improved Prostate Cancer-specific Survival and Other Disease Parameters: Impact of Prostate-specific Antigen Testing. Urology 2002; 60:756-759.
46. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38:83-91.
47. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58:417-424.
48. Barry MJ, Fleming C, Coley CM, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: management strategies and outcomes. Urology 1995; 46:277-289.
49. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin 2001; 51:38-75.
50. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntingt) 2000; 14:267-272, 277-268.
51. Moul JW. Screening for prostate cancer in African Americans. Curr Urol Rep 2000; 1:57-64.
52. Young CD, Lewis P, Weinberg V, et al. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy. Semin Urol Oncol 2000; 18:121-126.
53. Fowler JE, Jr., Bigler SA. Racial differences in prostate carcinogenesis. Histologic and clinical observations. Urol Clin North Am 2002; 29:183-191.
54. Fowler JJ, Bigler SA, Farabaugh PB, et al. Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml. J Urol 2000; 164:1961-1963.
55. Bunker CH, Patrick AL, Konety BR, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev 2002; 11:726-729.
56. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990; 17:337-347.
57. Spitz MR, Currier RD, Fueger JJ, et al. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991; 146:1305-1307.
58. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152:1484-1487.
59. Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996; 77:138-143.
60. Bauer JJ, Srivastava S, Connelly RR, et al. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998; 51:970-976.
61. Valeri A, Cormier L, Moineau MP, et al. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 2002; 168:483-487.
62. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
63. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58:411-416.
64. DeAntoni EP, Crawford ED, Oesterling JE, et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 1996; 48:234-239.
65. Hartzell JD, Kao T, Holland JC, et al. Age-specific reference ranges for prostate specific antigen in young men: retrospective study from the National Defense University. Prostate J 2002; 3:36-41.
66. Chautard D, Daver A, Mermod B, et al. Values for the free to total prostate-specific antigen ratio as a function of age: necessity of reference range validation. Eur Urol 1999; 36:181-186.
67. Weinrich MC, Jacobsen SJ, Weinrich SP, et al. Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology 1998; 52:967-973.
68. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154:1090-1095.
69. Anderson JR, Strickland D, Corbin D, et al. Age-specific reference ranges for serum prostate-specific antigen. Urology 1995; 46:54-57.
70. Cooney KA, Strawderman MS, Wojno KJ, et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 2001; 57:91-96.
71. Imai T. The author replies [letter]. Surg Endosc 2000; 14:1090.
72. Preston DM, Levin LI, Jacobson DJ, et al. Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 2000; 56:812-816.
73. Moul JW, Connely RR, Barko WF, et al. Should healthy men between the age of 40-49 be screened for prostate cancer: a Department of Defense (DOD), Center for Prostate Disease Research (CPDR), and Army Physical Fitness Research Institute (APFRI) prospective study at the U.S. Army War College (USAWC). J Urol 1999; 163 (suppl):4.
74. Moul JW, Sesterhenn LA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995; 274:1277-1281.
75. Moul JW, Connelly RR, Mooneyhan RM, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 1999; 162:394-397.
76. Smith DS, Carvalhal GF, Mager DE, et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998; 160:1734-1738.
77. Recker F, Kwiatkowski MK, Huber A, et al. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 2001; 166:851-855.
78. Nixon RG, Lilly JD, Liedtke RJ, et al. Variation of free and total prostate-specific antigen levels: the effect on the percent free/total prostate-specific antigen. Arch Pathol Lab Med 1997; 121:385-391.
79. Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/mL range in male volunteers. J Urol 1996; 155:1977-1980.
80. Morote J, Encabo G, Lopez M, et al. Individual variations of total and percent free serum prostatic specific antigen: could they change the indication of prostatic biopsy? Oncol Rep 1999; 6:887-890.
81. Ornstein DK, Smith DS, Rao GS, et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157:2179-2182.
82. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289:2695-2700.
83. Tchetgen MB, Song JT, Strawderman M, et al. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47:511-516.
84. Netto NR Jr, Apuzzo F, de Andrade E, et al. The effects of ejaculation on serum prostate specific antigen. J Urol 1996; 155:1329-1331.
85. Heidenreich A, Vorreuther R, Neubauer S, et al. The influence of ejaculation on serum levels of prostate specific antigen. J Urol 1997; 157:209-211.
86. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 1997; 50:239-243.
87. Yavascaoglu I, Savci V, Oktay B, et al. The effects of ejaculation on serum prostate-specific antigen (PSA). Int Urol Nephrol 1998; 30:53-58.
88. Stenner J, Holthaus K, Mackenzie SH, et al. The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology 1998; 51:455-459.
89. Zisman A, Soffer Y, Siegel YI, et al. Postejaculation serum prostate-specific antigen level. Eur Urol 1997; 32:54-57.
90. Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 2000; 88:615-619.
91. Jones HA, Metz JM, Devine P, et al. Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions. Urology 2002; 59:272-276.
92. Ostrow MJ, Cornelisse PG, Heath KV, et al. Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:115-120.
93. Allen T, Thomson WM, Emmerton LM, et al. Nutritional supplement use among 26-year-olds. N Z Med J 2000; 113:274-277.
94. Heuschkel R, Afzal N, Wuerth A, et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002; 97:382-388.
95. Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998; 51:1003-1007.
96. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996; 29:231-240.
97. Guess HA, Gormley GJ, Stoner E, et al. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155:3-9.
98. Cooper CS, Perry PJ, Sparks AE, et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998; 159:441-443.
99. Douglas TH, Connelly RR, McLeod DG, et al. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995; 59:246-250.
100. Oremek GM, Seiffert UB. Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. Clin Chem 1996; 42:691-695.
101. Crawford ED III, Mackenzie SH, Safford HR, et al. The effect of bicycle riding on serum prostate specific antigen levels. J Urol 1996; 156:103-105.
102. Swain RA, Montalto N, Ross D. The effect of long-distance cycling on the prostate-specific antigen level. Arch Fam Med 1997; 6:500-502.
103. Leventhal EK, Rozanski TA, Morey AF, et al. The effects of exercise and activity on serum prostate specific antigen levels. J Urol 1993; 150:893-894.
104. Tymchuk CN, Tessler SB, Aronson WJ, et al. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 1998; 31:127-131.
105. Roehl KA, Antenor JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol 2002; 168:922-925.
106. Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. J Urol 2002; 168:504-508.
107. Fang J, Metter EJ, Landis P, et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002; 59:889-893.
108. Ellis WJ, Etzioni R, Vessella RL, et al. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. J Urol 2001; 166:93-98.
109. Crawford ED, Chia D, Andriole GL, et al. PSA testing interval reduction in screening intervals: data from the prostate lung, colorectal and ovarian cancer (PLCO) screening trial. Proc Am Soc Clin Oncol 2002; 21:2a (Abstract #4).
110. Nijs HG, Essink-Bot ML, DeKoning HJ, et al. Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med 2000; 22:312-316.
111. Crawford ED, Leewansangtong S, Goktas S, et al. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4. 0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate 1999; 38:296-302.
112. Lujan Galan M, Paez Borda A, Romero Cajigal I, et al. [Role of PSA velocity in the detection of prostate cancer. A study of 986 males]. Actas Urol Esp 2001; 25:193-199.
113. Stirling BN, Shockley KF, Carothers GG, et al. Comparison of local anesthesia techniques during transrectal ultrasound-guided biopsies. Urology 2002; 60:89-92.
114. Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52:372-378.
115. Brawer MK, Cheli CD, Neaman IE, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163:1476-1480.
116. Maeda H, Arai Y, Aoki Y, et al. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology 1999; 54:225-228.
117. Okihara K, Cheli CD, Partin AW, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167:2017-2023.
118. Tanguay S, Begin LR, Elhilali MM, et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59:261-265.
119. Okihara K, Fritsche HA, Ayala A, et al. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol 2001; 165:1930-1936.
120. Horninger W, Cheli CD, Babaian RJ, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002; 60:31-35.
121. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577.
122. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-3614.
123. Cazares LH, Adam BL, Ward MD, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002; 8:2541-2552.